Literature DB >> 25524664

CD68 expression is a discriminative feature of indolent cutaneous CD8-positive lymphoid proliferation and distinguishes this lymphoma subtype from other CD8-positive cutaneous lymphomas.

M Wobser1, S Roth2, T Reinartz1, A Rosenwald2, M Goebeler1, E Geissinger2.   

Abstract

BACKGROUND: Indolent cutaneous CD8+ lymphoid proliferation is a recently described rare entity among cutaneous T-cell lymphomas that typically presents with solitary skin lesions at acral sites. Separation from otherwise aggressive T-cell lymphomas bearing a cytotoxic CD8+ phenotype is fundamental to avoid unnecessary harmful treatment. However, up to now, no reliable discriminative marker has been identified.
OBJECTIVES: Motivated by these diagnostic quandaries, we have analyzed a large series of archived formalin-fixed paraffin-embedded (FFPE) specimens of atypical CD8+ cutaneous infiltrates with clear-cut diagnosis and clinical follow-up (n = 44) including five cases of indolent CD8+ lymphoid proliferation by using immunohistochemistry with the aim of obtaining markers predictive of subtype assignment.
RESULTS: We identified exclusive expression of CD68 by lymphoma cells within the subgroup of indolent CD8+ lymphoid proliferation (5/5 cases). Specific CD68 expression in this entity was confirmed by the application of several monoclonal antibodies (KP1, PG-M1, KiM1P) against the CD68 molecule available for FFPE tissue. In contrast, none of the infiltrates of the other CD8+ cutaneous lymphoma entities stained positive for CD68 (0/39).
CONCLUSIONS: Based on these observations, we suggest CD68 as a new discriminative marker which is helpful in distinguishing indolent CD8+ lymphoid proliferation from other CD8+ cutaneous lymphomas in ambiguous cases.
© 2014 British Association of Dermatologists.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25524664     DOI: 10.1111/bjd.13628

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  5 in total

Review 1.  The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas.

Authors:  Rein Willemze; Lorenzo Cerroni; Werner Kempf; Emilio Berti; Fabio Facchetti; Steven H Swerdlow; Elaine S Jaffe
Journal:  Blood       Date:  2019-01-11       Impact factor: 22.113

Review 2.  Recent advances in cutaneous lymphoma-implications for current and future classifications.

Authors:  J R Goodlad; L Cerroni; S H Swerdlow
Journal:  Virchows Arch       Date:  2022-10-24       Impact factor: 4.535

3.  Cutaneous CD8+ Cytotoxic T-Cell Lymphoma Infiltrates: Clinicopathological Correlation and Outcome of 35 Cases.

Authors:  Marion Wobser; Theresa Reinartz; Sabine Roth; Matthias Goebeler; Andreas Rosenwald; Eva Geissinger
Journal:  Oncol Ther       Date:  2016-08-18

4.  An accurate diagnosis of dermal CD8+ lymphoproliferative disorders requires clinicopathological and immunophenotypic correlation.

Authors:  Alejandro A Gru
Journal:  Br J Dermatol       Date:  2022-05       Impact factor: 11.113

5.  Collisional variant of CD8+ mycosis fungoides and indolent CD8+ lymphoid proliferation.

Authors:  Adriana Lopez; Megan H Trager; Cynthia Magro; Larisa J Geskin
Journal:  JAAD Case Rep       Date:  2020-07-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.